Oxford Biomedica, a cell and gene therapy manufacturer, has cut its 2026 revenue forecast due to operational delays at its US site in Durham, North Carolina, and deferred client orders.
Revenue Forecast
The company now expects sales of £180 million to £200 million ($242.06 million to $268.96 million) in 2026, below its previous guidance of £220 million to £240 million. The stock fell to its lowest in nearly a year and was on track for its worst day since June 2013.
Oxford Biomedica had previously warned of a first-half core loss due to planned maintenance shutdowns and costs associated with the integration of its newly acquired facility in Durham, North Carolina. The company said changes in client ordering behavior, including delayed program timelines and altered procurement pathways of a large client, impacted revenue.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
